NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(4 sites)

Turkey (Türkiye)

Ankara Bilkent City Hospital - Hematology Clinic, Ankara

Ankara Etlik City Hospital - Hematology Clinic, Ankara

Hacettepe University Faculty of Medicine - Department of Internal Medicine, Division of Hematology, Ankara

University of Health Sciences Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara